Carlsmed, Inc. (CARL) – What Are Researchers Saying About This Stock?

Shares of Carlsmed, Inc. (NASDAQ:CARL) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $19.25.

Several equities analysts have commented on the company. Needham & Company LLC assumed coverage on Carlsmed in a research report on Wednesday, July 1st. They set a “buy” rating and a $17.00 price objective for the company. Weiss Ratings raised shares of Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. BTIG Research reissued a “buy” rating and set a $23.00 price target on shares of Carlsmed in a research report on Monday, September 28th. Truist Financial boosted their price objective on shares of Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Carlsmed Stock Performance

NASDAQ:CARL opened at $14.42 on Friday. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. The firm’s fifty day simple moving average is $14.93 and its 200 day simple moving average is $12.24. The stock has a market cap of $393.71 million, a P/E ratio of -10.08 and a beta of 2.09. Carlsmed has a twelve month low of $8.50 and a twelve month high of $17.23.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The business had revenue of $18.94 million during the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. As a group, research analysts predict that Carlsmed will post -1.50 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CARL. Zevenbergen Capital Investments LLC boosted its holdings in Carlsmed by 50.4% in the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock worth $252,000 after acquiring an additional 6,000 shares in the last quarter. Deutsche Bank AG bought a new position in shares of Carlsmed during the second quarter valued at $106,000. Bank of America Corp DE purchased a new position in shares of Carlsmed in the 2nd quarter worth about $108,000. Alpine Woods Capital Investors LLC bought a new position in Carlsmed in the 2nd quarter worth about $161,000. Finally, Bank of New York Mellon Corp purchased a new stake in Carlsmed during the 2nd quarter valued at about $181,000.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address spinal deformity and degenerative conditions with procedures tailored to an individual patient’s anatomy and surgical goals.

Its principal products are offered under the aprevo brand and include personalized interbody fusion implants produced using three-dimensional printing, along with software that supports implant design and preoperative planning.